Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 10 | 2019 | 465 | 0.930 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 327 | 0.760 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2021 | 259 | 0.570 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2021 | 62 | 0.560 |
Why?
|
| ras Proteins | 3 | 2016 | 78 | 0.500 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 53 | 0.470 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2014 | 10 | 0.460 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 31 | 0.440 |
Why?
|
| Immunohistochemistry | 10 | 2020 | 852 | 0.420 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2019 | 75 | 0.400 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 316 | 0.390 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 114 | 0.390 |
Why?
|
| Pancreatic Neoplasms | 4 | 2019 | 326 | 0.380 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 419 | 0.370 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 1128 | 0.370 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 710 | 0.350 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 761 | 0.320 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 6 | 0.320 |
Why?
|
| Receptor, ErbB-4 | 2 | 2019 | 8 | 0.320 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2019 | 10 | 0.320 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2021 | 24 | 0.310 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 24 | 0.310 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 207 | 0.280 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 155 | 0.270 |
Why?
|
| Mutation | 5 | 2019 | 2464 | 0.240 |
Why?
|
| Cervix Uteri | 2 | 2020 | 57 | 0.200 |
Why?
|
| Celiac Disease | 1 | 2002 | 17 | 0.190 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 910 | 0.190 |
Why?
|
| Microscopy | 1 | 2022 | 88 | 0.190 |
Why?
|
| Aged | 14 | 2021 | 13550 | 0.190 |
Why?
|
| Cyst Fluid | 2 | 2019 | 5 | 0.180 |
Why?
|
| Urine | 1 | 2021 | 36 | 0.180 |
Why?
|
| Lymph Nodes | 1 | 2002 | 213 | 0.180 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2018 | 30 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2021 | 36 | 0.180 |
Why?
|
| Colposcopy | 1 | 2020 | 22 | 0.180 |
Why?
|
| Female | 18 | 2021 | 31187 | 0.180 |
Why?
|
| Adenosarcoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 6 | 0.170 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 13 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2020 | 17 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 29 | 0.170 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 31 | 0.170 |
Why?
|
| Humans | 27 | 2022 | 60044 | 0.170 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 55 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 577 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2012 | 105 | 0.160 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 8 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 146 | 0.160 |
Why?
|
| Middle Aged | 13 | 2020 | 16498 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 277 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 56 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 1100 | 0.150 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 5181 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 330 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 192 | 0.140 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 196 | 0.140 |
Why?
|
| Pancreas | 2 | 2019 | 146 | 0.140 |
Why?
|
| Histiocytes | 1 | 2016 | 5 | 0.130 |
Why?
|
| Histiocytosis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Lipase | 1 | 2017 | 49 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 298 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 299 | 0.130 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 15 | 0.130 |
Why?
|
| Urothelium | 1 | 2016 | 22 | 0.130 |
Why?
|
| Adult | 10 | 2020 | 15949 | 0.130 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 31 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 77 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2022 | 63 | 0.120 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 24 | 0.120 |
Why?
|
| Fixatives | 1 | 2014 | 17 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 201 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2016 | 166 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 99 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 50 | 0.110 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2014 | 24 | 0.110 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2014 | 3 | 0.110 |
Why?
|
| Male | 12 | 2021 | 27910 | 0.110 |
Why?
|
| Pathology | 1 | 2013 | 11 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 38 | 0.110 |
Why?
|
| Melanocytes | 1 | 2013 | 78 | 0.100 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 17 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 29 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 405 | 0.090 |
Why?
|
| Melanoma | 1 | 2013 | 334 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 127 | 0.080 |
Why?
|
| Prognosis | 3 | 2018 | 1588 | 0.080 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 388 | 0.080 |
Why?
|
| Cytodiagnosis | 2 | 2022 | 44 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 8 | 0.070 |
Why?
|
| Flutamide | 1 | 2007 | 4 | 0.070 |
Why?
|
| Leuprolide | 1 | 2007 | 14 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 793 | 0.070 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 21 | 0.070 |
Why?
|
| Mesentery | 1 | 2002 | 14 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2022 | 23 | 0.050 |
Why?
|
| Curettage | 1 | 2020 | 8 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 514 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 13 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 114 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 196 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 11 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 118 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 75 | 0.040 |
Why?
|
| beta Catenin | 1 | 2018 | 85 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 142 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 397 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 73 | 0.040 |
Why?
|
| Oncogenes | 1 | 2018 | 68 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 272 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 458 | 0.040 |
Why?
|
| Amylases | 1 | 2017 | 11 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 33 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 40 | 0.030 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2016 | 49 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4384 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 26 | 0.030 |
Why?
|
| DNA | 1 | 2019 | 793 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 376 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 498 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 21 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 32 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 38 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 41 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2015 | 72 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2361 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2014 | 113 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 20 | 0.030 |
Why?
|
| Breast | 1 | 2015 | 173 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 6125 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 56 | 0.030 |
Why?
|
| Hybridomas | 1 | 2012 | 65 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 3126 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 72 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1210 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 196 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 835 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 880 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1565 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1034 | 0.020 |
Why?
|
| Pancreatitis, Chronic | 1 | 2008 | 22 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 857 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 248 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2007 | 51 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 274 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 67 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5255 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 5949 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 10311 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 19727 | 0.010 |
Why?
|